Efficacy and safety profile of busulfan plus low dose melphalan (BUMEL) versus high dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cells transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis

Key Points

• This research aims to evaluate the efficacy and safety of busulfan plus low dose melphalan versus high dose melphalan for autologous stem cell transplantation in multiple myeloma.
• Conducted a systematic review and meta-analysis of existing studies.
• Compared outcomes of BUMEL with MEL200 conditioning regimens.
• Analyzed disease control and toxicity levels.
• BUMEL showed improved disease control compared to MEL200.
• Increased toxicity was noted with the BUMEL regimen.
• No clear advantage in overall survival was identified between the two regimens.

Abstract